Solid Biosciences (SLDB) Competitors

$7.63 +0.25 (+3.39%)

Closing price 04:00 PM Eastern

Extended Trading

$7.72 +0.09 (+1.11%)

As of 05:16 PM Eastern

SLDB vs. TARS, KLRA, IMNM, IRON, and VERA

Should you buy Solid Biosciences stock or one of its competitors? MarketBeat compares Solid Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Solid Biosciences include Tarsus Pharmaceuticals (TARS), Kailera Therapeutics (KLRA), Immunome (IMNM), Disc Medicine (IRON), and Vera Therapeutics (VERA). These companies are all part of the "pharmaceutical products" industry.

How does Solid Biosciences compare to Tarsus Pharmaceuticals?

Tarsus Pharmaceuticals (NASDAQ:TARS) and Solid Biosciences (NASDAQ:SLDB) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, media sentiment, institutional ownership, valuation and profitability.

Tarsus Pharmaceuticals has a beta of 0.52, suggesting that its stock price is 48% less volatile than the broader market. Comparatively, Solid Biosciences has a beta of 2.47, suggesting that its stock price is 147% more volatile than the broader market.

Tarsus Pharmaceuticals presently has a consensus target price of $90.67, indicating a potential upside of 39.10%. Solid Biosciences has a consensus target price of $16.36, indicating a potential upside of 114.46%. Given Solid Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Solid Biosciences is more favorable than Tarsus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.78
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92

Tarsus Pharmaceuticals has higher revenue and earnings than Solid Biosciences. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tarsus Pharmaceuticals	$451.36M	6.21	-$66.42M	-$1.14	N/A
Solid Biosciences	N/A	N/A	-$174.32M	-$1.95	N/A

In the previous week, Tarsus Pharmaceuticals had 22 more articles in the media than Solid Biosciences. MarketBeat recorded 30 mentions for Tarsus Pharmaceuticals and 8 mentions for Solid Biosciences. Tarsus Pharmaceuticals' average media sentiment score of 0.16 beat Solid Biosciences' score of -0.31 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tarsus Pharmaceuticals	6 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Solid Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Solid Biosciences has a net margin of 0.00% compared to Tarsus Pharmaceuticals' net margin of -9.02%. Tarsus Pharmaceuticals' return on equity of -14.19% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tarsus Pharmaceuticals	-9.02%	-14.19%	-8.89%
Solid Biosciences	N/A	-86.46%	-69.64%

90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. Comparatively, 81.5% of Solid Biosciences shares are held by institutional investors. 9.6% of Tarsus Pharmaceuticals shares are held by company insiders. Comparatively, 1.9% of Solid Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Tarsus Pharmaceuticals beats Solid Biosciences on 10 of the 16 factors compared between the two stocks.

How does Solid Biosciences compare to Kailera Therapeutics?

Solid Biosciences (NASDAQ:SLDB) and Kailera Therapeutics (NASDAQ:KLRA) are both pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, profitability, dividends and analyst recommendations.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solid Biosciences	N/A	N/A	-$174.32M	-$1.95	N/A
Kailera Therapeutics	N/A	N/A	N/A	N/A	N/A

In the previous week, Kailera Therapeutics had 3 more articles in the media than Solid Biosciences. MarketBeat recorded 11 mentions for Kailera Therapeutics and 8 mentions for Solid Biosciences. Kailera Therapeutics' average media sentiment score of 0.63 beat Solid Biosciences' score of -0.31 indicating that Kailera Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solid Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kailera Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Solid Biosciences presently has a consensus price target of $16.36, indicating a potential upside of 114.46%. Kailera Therapeutics has a consensus price target of $42.75, indicating a potential upside of 98.84%. Given Solid Biosciences' higher possible upside, equities research analysts plainly believe Solid Biosciences is more favorable than Kailera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92
Kailera Therapeutics	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.17

Kailera Therapeutics' return on equity of 0.00% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solid Biosciences	N/A	-86.46%	-69.64%
Kailera Therapeutics	N/A	N/A	N/A

81.5% of Solid Biosciences shares are owned by institutional investors. 1.9% of Solid Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Kailera Therapeutics beats Solid Biosciences on 5 of the 9 factors compared between the two stocks.

How does Solid Biosciences compare to Immunome?

Solid Biosciences (NASDAQ:SLDB) and Immunome (NASDAQ:IMNM) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends, media sentiment and earnings.

Solid Biosciences has higher earnings, but lower revenue than Immunome. Immunome is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solid Biosciences	N/A	N/A	-$174.32M	-$1.95	N/A
Immunome	$4.02M	621.11	-$212.39M	-$2.38	N/A

Solid Biosciences has a beta of 2.47, meaning that its share price is 147% more volatile than the broader market. Comparatively, Immunome has a beta of 2.11, meaning that its share price is 111% more volatile than the broader market.

Immunome's return on equity of -57.71% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solid Biosciences	N/A	-86.46%	-69.64%
Immunome	N/A	-57.71%	-52.69%

Solid Biosciences currently has a consensus price target of $16.36, suggesting a potential upside of 114.46%. Immunome has a consensus price target of $33.45, suggesting a potential upside of 51.93%. Given Solid Biosciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe Solid Biosciences is more favorable than Immunome.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92
Immunome	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91

In the previous week, Immunome had 4 more articles in the media than Solid Biosciences. MarketBeat recorded 12 mentions for Immunome and 8 mentions for Solid Biosciences. Immunome's average media sentiment score of 0.97 beat Solid Biosciences' score of -0.31 indicating that Immunome is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solid Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Immunome	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

81.5% of Solid Biosciences shares are held by institutional investors. Comparatively, 44.6% of Immunome shares are held by institutional investors. 1.9% of Solid Biosciences shares are held by insiders. Comparatively, 7.2% of Immunome shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Solid Biosciences beats Immunome on 8 of the 14 factors compared between the two stocks.

How does Solid Biosciences compare to Disc Medicine?

Disc Medicine (NASDAQ:IRON) and Solid Biosciences (NASDAQ:SLDB) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

Disc Medicine's return on equity of -36.94% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Disc Medicine	N/A	-36.94%	-33.88%
Solid Biosciences	N/A	-86.46%	-69.64%

Disc Medicine has a beta of 0.93, meaning that its stock price is 7% less volatile than the broader market. Comparatively, Solid Biosciences has a beta of 2.47, meaning that its stock price is 147% more volatile than the broader market.

Disc Medicine currently has a consensus price target of $105.30, suggesting a potential upside of 51.08%. Solid Biosciences has a consensus price target of $16.36, suggesting a potential upside of 114.46%. Given Solid Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Solid Biosciences is more favorable than Disc Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92

In the previous week, Disc Medicine had 6 more articles in the media than Solid Biosciences. MarketBeat recorded 14 mentions for Disc Medicine and 8 mentions for Solid Biosciences. Disc Medicine's average media sentiment score of 0.49 beat Solid Biosciences' score of -0.31 indicating that Disc Medicine is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Disc Medicine	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Solid Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

83.7% of Disc Medicine shares are held by institutional investors. Comparatively, 81.5% of Solid Biosciences shares are held by institutional investors. 3.8% of Disc Medicine shares are held by company insiders. Comparatively, 1.9% of Solid Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Disc Medicine is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Disc Medicine	N/A	N/A	-$212.18M	-$6.62	N/A
Solid Biosciences	N/A	N/A	-$174.32M	-$1.95	N/A

Summary

Solid Biosciences beats Disc Medicine on 8 of the 14 factors compared between the two stocks.

How does Solid Biosciences compare to Vera Therapeutics?

Vera Therapeutics (NASDAQ:VERA) and Solid Biosciences (NASDAQ:SLDB) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations, profitability and earnings.

Vera Therapeutics currently has a consensus target price of $79.60, suggesting a potential upside of 101.21%. Solid Biosciences has a consensus target price of $16.36, suggesting a potential upside of 114.46%. Given Solid Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Solid Biosciences is more favorable than Vera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92

In the previous week, Vera Therapeutics had 11 more articles in the media than Solid Biosciences. MarketBeat recorded 19 mentions for Vera Therapeutics and 8 mentions for Solid Biosciences. Vera Therapeutics' average media sentiment score of 0.18 beat Solid Biosciences' score of -0.31 indicating that Vera Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vera Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Solid Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Vera Therapeutics has a beta of 0.96, meaning that its stock price is 4% less volatile than the broader market. Comparatively, Solid Biosciences has a beta of 2.47, meaning that its stock price is 147% more volatile than the broader market.

Vera Therapeutics is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.54	N/A
Solid Biosciences	N/A	N/A	-$174.32M	-$1.95	N/A

Vera Therapeutics' return on equity of -74.86% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vera Therapeutics	N/A	-74.86%	-60.18%
Solid Biosciences	N/A	-86.46%	-69.64%

99.2% of Vera Therapeutics shares are held by institutional investors. Comparatively, 81.5% of Solid Biosciences shares are held by institutional investors. 15.9% of Vera Therapeutics shares are held by company insiders. Comparatively, 1.9% of Solid Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Solid Biosciences beats Vera Therapeutics on 8 of the 14 factors compared between the two stocks.

Get Solid Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SLDB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SLDB vs. The Competition

Export

Metric	Solid Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$750.89M	$3.40B	$6.29B	$12.46B
Dividend Yield	N/A	2.31%	2.79%	5.30%
P/E Ratio	-3.91	18.81	20.87	25.58
Price / Sales	N/A	181.67	521.63	63.56
Price / Cash	N/A	122.51	42.94	55.34
Price / Book	3.35	6.74	9.86	6.70
Net Income	-$174.32M	$24.11M	$3.55B	$333.77M
7 Day Performance	7.92%	0.07%	-0.32%	0.45%
1 Month Performance	-7.29%	0.84%	1.34%	4.06%
1 Year Performance	199.22%	78.10%	41.03%	36.21%

Solid Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SLDB Solid Biosciences	2.9107 of 5 stars	$7.63 +3.4%	$16.36 +114.5%	+164.5%	$750.89M	N/A	N/A	100	News Coverage Earnings Report Analyst Forecast
TARS Tarsus Pharmaceuticals	3.111 of 5 stars	$63.96 -1.2%	$90.67 +41.8%	+56.0%	$2.79B	$451.36M	N/A	50	Analyst Revision High Trading Volume
KLRA Kailera Therapeutics	4.9072 of 5 stars	$22.47 -9.0%	N/A	N/A	$2.78B	N/A	N/A	145	News Coverage Analyst Forecast Short Interest Increase
IMNM Immunome	3.5015 of 5 stars	$22.19 -4.6%	$33.45 +50.8%	+180.7%	$2.64B	$6.94M	N/A	40	Earnings Report Analyst Forecast Analyst Revision
IRON Disc Medicine	2.3961 of 5 stars	$67.53 -1.6%	$104.80 +55.2%	+51.1%	$2.62B	N/A	N/A	30	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SLDB) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Solid Biosciences (SLDB) Competitors

SLDB vs. TARS, KLRA, IMNM, IRON, and VERA

How does Solid Biosciences compare to Tarsus Pharmaceuticals?

Summary

How does Solid Biosciences compare to Kailera Therapeutics?

Summary

How does Solid Biosciences compare to Immunome?

Summary

How does Solid Biosciences compare to Disc Medicine?

Summary

How does Solid Biosciences compare to Vera Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLDB vs. The Competition

Solid Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Solid Biosciences (SLDB) Competitors

SLDB vs. TARS, KLRA, IMNM, IRON, and VERA

How does Solid Biosciences compare to Tarsus Pharmaceuticals?

Which has more risk and volatility, TARS or SLDB?

Do analysts rate TARS or SLDB?

Which has better earnings and valuation, TARS or SLDB?

Does the media favor TARS or SLDB?

Is TARS or SLDB more profitable?

Do institutionals and insiders believe in TARS or SLDB?

Summary

How does Solid Biosciences compare to Kailera Therapeutics?

Which has stronger valuation & earnings, SLDB or KLRA?

Does the media prefer SLDB or KLRA?

Do analysts recommend SLDB or KLRA?

Is SLDB or KLRA more profitable?

Do insiders and institutionals have more ownership in SLDB or KLRA?

Summary

How does Solid Biosciences compare to Immunome?

Which has better earnings & valuation, SLDB or IMNM?

Which has more volatility & risk, SLDB or IMNM?

Is SLDB or IMNM more profitable?

Do analysts rate SLDB or IMNM?

Does the media prefer SLDB or IMNM?

Do insiders & institutionals have more ownership in SLDB or IMNM?

Summary

How does Solid Biosciences compare to Disc Medicine?

Is IRON or SLDB more profitable?

Which has more volatility and risk, IRON or SLDB?

Do analysts rate IRON or SLDB?

Does the media prefer IRON or SLDB?

Do institutionals and insiders hold more shares of IRON or SLDB?

Which has stronger valuation & earnings, IRON or SLDB?

Summary

How does Solid Biosciences compare to Vera Therapeutics?

Do analysts recommend VERA or SLDB?

Does the media favor VERA or SLDB?

Which has more risk & volatility, VERA or SLDB?

Which has better earnings and valuation, VERA or SLDB?

Is VERA or SLDB more profitable?

Do insiders & institutionals believe in VERA or SLDB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLDB vs. The Competition

Solid Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools